IDEXX Laboratories, Inc. $IDXX Shares Acquired by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 213.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 300,197 shares of the company’s stock after buying an additional 204,307 shares during the period. IDEXX Laboratories accounts for approximately 0.9% of AustralianSuper Pty Ltd’s holdings, making the stock its 19th biggest holding. AustralianSuper Pty Ltd’s holdings in IDEXX Laboratories were worth $203,092,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories during the second quarter worth about $30,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $31,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $35,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. This represents a 11.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 34,612 shares of company stock valued at $22,525,070. 0.79% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $532.86 on Friday. The company has a market cap of $42.03 billion, a P/E ratio of 39.24, a PEG ratio of 3.08 and a beta of 1.58. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a one year low of $496.61 and a one year high of $769.98. The business’s 50-day simple moving average is $574.48 and its 200 day simple moving average is $646.38.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business earned $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.66 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.